News
Find the latest press releases and communications on our news section.
Complete Enrollment Achieved for the Clinical Phase 2 ASURE Study: Advancing Alzheimer’s Disease Research
Tilburg, 17 September 2024 - Treeway is pleased to announce the successful completion of patient enrollment for the Phase 2A ASURE study. The study is the first randomized, double-blind, placebo-controlled trial aiming to evaluate the safety, pharmacodynamics, and pharmacokinetics of oral...
Top-line results from Phase III ADORE study in ALS
In reference to the official press release of our pharma partner Ferrer, we regret to share that the top-line results of the phase 3 clinical study ADORE* show that the primary or key secondary endpoints were not met. In the ADORE study, our lead product TW001 (FAB122 for Ferrer), an oral version...
Treeway Licensing Deal with Specialised Therapeutics
Singapore, August 28th, 2023 –Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Netherlands based biotechnology company Treeway BV to commercialise a new therapy to treat Amyotrophic Lateral Sclerosis (ALS)¹ – the most common form of Motor Neurone...
Treeway announces first patient enrolled in the Phase 2a ASURE clinical trial exploring the safety and effectiveness of oral edaravone to delay disease progression in Alzheimer’s patients
Tilburg, March 6, 2023 – Treeway, in collaboration with the Alzheimer Drug Discovery Foundation (ADDF), announces today the successful enrollment of the first patient in the Alzheimer’s Disease Study Using Oral Edaravone (ASURE), Phase 2a clinical trial. The trial will include 60 patients in...
Phase III clinical trial TW001/FNP122 for ALS, partnered with Ferrer
With the licensing agreement between Treeway and Ferrer in place, FNP122 (formerly TW001) has now entered clinical stage phase III with the initiation of the ADORE study (ALS Deceleration study with Oral Edaravone). In a large-scale double-blind placebo-controlled clinical trial, Ferrer will test...
Ferrer announces first patient enrollment of FNP122 in ADORE Phase III clinical trial for Amyotrophic Lateral Sclerosis treatment
Barcelona, November 9th, 2021 – Ferrer, an international pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has today announced the next major milestone in its mission to develop transformative therapies for Amyotrophic Lateral...
Ferrer and Treeway enter into licence agreement for the development and commercialisation of TW001/FNP122 for Amyotrophic Lateral Sclerosis
Ferrer and Treeway announced they have entered into a licence agreement for the development and commercialisation of an oral formulation of edaravone (TW001/FNP122)[i] for ALS in certain territories, including Europe and some Asian countries.
Rare Disease Symposium April 18th
On Thursday April 18, Treeway’s CEO Inez de Greef is a speaker at the Rare Diseases Symposium.
Treeway Announces Promising Data from Phase I Clinical Trial of Lead
Study suggests that novel oral formulation of edaravone improves bioavailability while remaining well tolerated.
Australian Motor Neurone Disease Symposium
This week, the Australian Motor Neurone Disease Symposium takes place in Melbourne, Australia.